Femasys Says It Received US Patent for Female Birth Control Device FemBloc-June 2024-www.financetom.com

Femasys Says It Received US Patent for Female Birth Control Device FemBloc

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Femasys Says It Received US Patent for Female Birth Control Device FemBloc

Nov 4, 2024 12:06 PM

08:53 AM EDT, 11/01/2024 (MT Newswires) -- Femasys ( FEMY ) said Friday that it received a new US patent covering FemBloc, its permanent, non-surgical birth control device for women.

The company said the patent, valid until at least 2039, supports Femasys' ( FEMY ) intellectual property protection for FemBloc as it progresses through clinical trials.

Femasys ( FEMY ) plans to apply for more patents for FemBloc and other products, the company added.

Previous page： Deals of the day-Mergers and acquisitions Next page： Power Nickel Provides Additional Assays from Lion Zone in Quebec

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Deals of the day-Mergers and acquisitions

May 4, 2026

May 4 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1200 GMT on Monday: ** Electrical equipment maker Hubbell said it had agreed to acquire peer NSI Industries, a portfolio company of Sentinel Capital Partners, for $3 billion in cash. ** Spanish energy group Repsol has agreed to sell a 49% stake in its largest portfolio...

Power Nickel Provides Additional Assays from Lion Zone in Quebec

May 4, 2026

08:11 AM EDT, 05/04/2026 (MT Newswires) -- Power Metallic Mines' ( PNPNF ) latest drilling continued to define the high-grade Lion zone within the Nisk project in Quebec. Additional assays from a winter 2026 drill program include 17.45 meters of 9.47% copper equivalent and 39 m of 5.66% copper equivalent. The results will support a mineral resource estimate expected in...

Takeda's immune disease drug meets main goal of mid-to-late stage trial

May 4, 2026

May 4 (Reuters) - Takeda Pharmaceutical ( TAK ) said its experimental drug for primary immunodeficiency disease, a rare condition that weakens the immune system, has met the main goal of a mid- to late-stage clinical trial. ...

Hubbell to Acquire NSI Industries in $3 Billion Deal

May 4, 2026

08:10 AM EDT, 05/04/2026 (MT Newswires) -- Hubbell (HUBB) agreed to acquire NSI Industries, a portfolio company of Sentinel Capital Partners, for about $3 billion in cash in a deal expected to strengthen its electrical solutions portfolio, the company said Monday. The company expects the deal to be accretive to adjusted earnings per share in 2026 and to improve operating...